SB772077B | CAS#unknown | ROCK-1 inhibitor

MedKoo Cat#: 464031 | Name: SB772077B

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB772077B is an orally bioavailable ROCK-1 inhibitor.

Chemical Structure

SB772077B

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 464031

Name: SB772077B

CAS#: unknown

Chemical Formula: C15H18N8O2

Exact Mass: 342.1553

Molecular Weight: 342.36

Elemental Analysis: C, 52.62; H, 5.30; N, 32.73; O, 9.35

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SB772077B; SB 772077B; SB-772077B;

IUPAC/Chemical Name

(S)-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl)(3-aminopyrrolidin-1-yl)methanone

InChi Key

PHWHNHYZZNJPLB-QMMMGPOBSA-N

InChi Code

InChI=1S/C15H18N8O2/c1-2-23-12-9(15(24)22-4-3-8(16)7-22)5-18-6-10(12)19-14(23)11-13(17)21-25-20-11/h5-6,8H,2-4,7,16H2,1H3,(H2,17,21)/t8-/m0/s1

SMILES Code

NC1=NON=C1C2=NC3=C(N2CC)C(C(N4CC[C@H](N)C4)=O)=CN=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 342.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ashwinbalaji S, Haribalaganesh R, Krishnadas S, Muthukkaruppan V, Senthilkumari S. SB772077B (SB77) Alleviated the Aqueous Outflow Resistance Mediated by Cyclic Mechanical Stress in Perfused Human Cadaveric Eyes. Sci Rep. 2020 Jun 23;10(1):10202. doi: 10.1038/s41598-020-67087-2. PMID: 32576873; PMCID: PMC7311383. 2: Ashwinbalaji S, Senthilkumari S, Gowripriya C, Krishnadas S, Gabelt BAT, Kaufman PL, Muthukkaruppan V. SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes. Sci Rep. 2018 Oct 19;8(1):15472. doi: 10.1038/s41598-018-33932-8. PMID: 30341380; PMCID: PMC6195566. 3: Cazzola M, Calzetta L, Rogliani P, Lauro D, Novelli L, Page CP, Kanabar V, Matera MG. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. Am J Respir Cell Mol Biol. 2012 Oct;47(4):509-16. doi: 10.1165/rcmb.2011-0449OC. Epub 2012 May 31. PMID: 22652200. 4: Antoniu SA. Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert Opin Ther Targets. 2012 Apr;16(4):355-63. doi: 10.1517/14728222.2012.671811. Epub 2012 Mar 27. PMID: 22449260. 5: Dhaliwal JS, Badejo AM Jr, Casey DB, Murthy SN, Kadowitz PJ. Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)ca rbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor. J Pharmacol Exp Ther. 2009 Jul;330(1):334-41. doi: 10.1124/jpet.109.151449. Epub 2009 Apr 15. PMID: 19369577; PMCID: PMC2700172. 6: Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. doi: 10.1124/jpet.106.110635. Epub 2006 Oct 3. PMID: 17018693.